At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
CC-10004drug
Likely dose
CC-10004 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis
University Hospitals Cleveland Medical Center·interventional·Posted Mar 25, 2009·Updated Nov 2, 2016
In Brief
A Phase 2 clinical trial evaluating CC-10004 for Prurigo Nodularis. Completed, enrolled 5 participants across 1 site.
Detailed Summary
This trial will include: * Study period up to 7 months. * Office visits monthly lasting approximately 1 hour. * Blood Draws. * Oral medication that is taken 2 times daily. * Photographs and biopsies if agreed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedMar 2009
Primary CompletionJan 2011
TodayJul 2026
First PostedMar 25, 2009
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.3 years ago
Interventions
CC-10004drug
30mg,oral medication, BID, for 24 weeks (60mg total DAILY)